arrow
C

Camilla Muccini

vita-salute san raffaele university
H指数:16
被引数:1,389

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Development, validation and clinical implementation of a HPLC-MS/MS method for the simultaneous quantification of bictegravir, emtricitabine, doravirine, cabotegravir, lenacapavir, fostemsavir, tenofovir alafenamide and the corresponding metabolites temsavir and tenofovir, in human plasma

开发、验证及临床实施一种HPLC-MS/MS方法,用于同时定量测定人血浆中bictegravir、emtricitabine、doravirine、cabotegravir、lenacapavir、fostemsavir、tenofovir alafenamide及其对应代谢物temsavir和tenofovir。

2025-10-010
PRE
Antimicrobial use for the treatment of bacterial sexually transmitted infections among doxycycline post-exposure prophylaxis (DoxyPEP) users in Milan, Italy

在米兰,意大利,多西环素暴露后预防(DoxyPEP)使用者中用于治疗细菌性性传播感染的抗菌药物使用情况。

2025-07-011
PRE
Effectiveness and predictors of treatment discontinuation of long-acting cabotegravir/rilpivirine in virologically suppressed people with HIV: real-life data from the Icona Cohort

长效卡博特格拉韦/利匹韦林治疗中断的有效性及预测因素:来自Icona队列的真实世界数据,用于研究病毒学受抑制的HIV感染者

2025-06-011
PRE
Time to HIV viral rebound and frequency of post-treatment control after analytical interruption of antiretroviral therapy: an individual data-based meta-analysis of 24 prospective studies

抗逆转录病毒治疗分析性中断后,HIV病毒反弹时间和治疗后控制频率:一项基于24项前瞻性研究的个体数据meta分析

2025-01-212
OA
Two-fold increased risk of cardiovascular events in people with MDR HIV: a matched cohort analysis with data from the PRESTIGIO registry

MDR HIV患者的心血管事件风险增加两倍: 与PRESTIGIO注册中心数据匹配的队列分析

2024-12-270
PRE
In-depth Analysis of the HIV Reservoir Confirms Effectiveness and Safety of Dolutegravir/Lamivudine in a Phase 4 Randomized Controlled Switch Trial (RUMBA)
2024-09-031
OAAI